SSY GROUP (02005) announced that the group has obtained a drug production registration certificate from China's National Medical Products Administration (NMPA) for Benidipine Hydrochloride Tablets (8mg). The product is classified as a Category 4 chemical drug and is deemed to have passed consistency evaluation. Benidipine Hydrochloride Tablets are primarily used for treating primary hypertension and angina. As disclosed in the company's announcement dated January 6, 2025, the group's benidipine hydrochloride active pharmaceutical ingredient had already received NMPA approval for registration as an active ingredient for use in marketed formulations.